SCHEMBL4212914

SCHEMBL4212914

CCC#CCCCCCCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.54
HMGCR P04035 2/20 0.54
RECQL P46063 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
TSHR P16473 2/20 0.47
THRB P10828 1/20 0.47
ALDH1A1 P00352 2/20 0.45
ALOX12 P18054 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
BLM P54132 1/20 0.45
KMT2A Q03164 1/20 0.45
MCL1 Q07820 1/20 0.45
SLC22A1 O15245 1/20 0.43
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6467458 1.00 PTPN7 (0.54) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9015885 1.00 PTPN7 (0.54) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9015928 1.00 PTPN7 (0.54) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL4223277 1.00 PTPN7 (0.54) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL4224620 1.00 PTPN7 (0.54) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL55675 1.00 PTPN7 (0.54) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL161365 1.00 PTPN7 (0.54) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9015846 1.00 PTPN7 (0.54) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9015963 1.00 PTPN7 (0.54) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL6468299 1.00 PTPN7 (0.54) PTPN7HMGCRRECQLTDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS FLAGSHIP LABS 114, INC. (US) 2026-05-14 US claimed
EP-4687854-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY Flagship Labs 114, Inc. (US) 2026-02-11 EP claimed
WO-2024211865-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY OMEGA THERAPEUTICS, INC. (US) 2024-10-10 WO claimed
WO-2024073678-A2 PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE OMEGA THERAPEUTICS, INC. (US) 2024-04-04 WO claimed
CN-117309954-A Method for evaluating quality of grass nuts and processing quality of grass nuts and application of grass nuts 山东省中医药研究院 2023-12-29 CN claimed
WO-2023225621-A2 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS OMEGA THERAPEUTICS, INC. (US) 2023-11-23 WO claimed
US-9568821-B2 Patterning process SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-02-14 US claimed
US-9507262-B2 Resist top-coat composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-11-29 US claimed
US-20150234278-A1 PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2015-08-20 US claimed
US-20150234274-A1 RESIST TOP-COAT COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2015-08-20 US claimed
EP-2181763-B1 Catalyst and process for alkoxylation SHELL INT RESEARCH (NL) 2012-06-20 EP claimed
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS FLAGSHIP LABS 114, INC. (US) 2026-05-14 US disclosed
US-12616728-B2 Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same SUPER CRITICAL IP, LLC (US) 2026-05-05 US disclosed
US-12590219-B2 Phenol compound, conductive paste composition, method for producing conductive paste composition, conductive wire, and method for producing conductive wire SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-03-31 US disclosed
EP-4687854-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY Flagship Labs 114, Inc. (US) 2026-02-11 EP disclosed
US-20150234278-A1 PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2015-08-20 US disclosed
CN-102084295-A Molecular resist composition, method of forming substrate pattern using the same, and product prepared therefrom NANO TERRA INC 2011-06-01 CN disclosed
US-20090317617-A1 BASE MEMBER WITH BINDING FILM, BONDING METHOD, AND BONDED STRUCTURE SEIKO EPSON CORPORATION (JP) 2009-12-24 US disclosed
CN-1441785-A Tetrahydroixoquinoline analogs useful as growth hormone secretagogues BRISTOL MYERS SQUIBB CO (US) 2003-09-10 CN disclosed
EP-0748823-A1 Catalyst composition and process for the production of olefinic polymers NIPPON OIL CO. LTD. (JP) 1996-12-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616728-B2 Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same CNR2, CNR1, SCD PTPN7 3826/4885HMGCR 163/4885RECQL 2932/4885
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS NSUN3, NSUN2, LDLR PTPN7 2194/4885HMGCR 460/4885RECQL 976/4885
US-12590219-B2 Phenol compound, conductive paste composition, method for producing conductive paste composition, conductive wire, and method for producing conductive wire PYCARD, NPR1, TNNC1 PTPN7 2430/4885HMGCR 4671/4885RECQL 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.